Search

Your search keyword '"de la Rosette, Jean"' showing total 2,202 results
Start Over Author "de la Rosette, Jean"
2,202 results on '"de la Rosette, Jean"'

2. Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society

Author

Baard, Joyce, Celebi, Merve, de la Rosette, Jean, Alcaraz, Antonio, Shariat, Shahrokh, Cormio, Luigi, Cavadas, Vítor, and Laguna, M Pilar

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundAvailable guidelines on the management of upper tract urothelial carcinoma (UTUC) are restricted due to the lack of strong evidence–based recommendations. Adequate, well-powered randomized trials are missing due to the rarity of the disease. To overcome this problem, we need alternative study designs to provide generalizable data. ObjectiveThe primary aim of this registry is to provide a real-world overview on patterns of presentation and management of UTUC. Secondary objectives include comparison of outcomes of different treatments and tumor stages and evaluation of compliance with the current European Association of Urology recommendations for UTUC. MethodsFor this observational, international, multicenter, cohort study, clinical data of consecutive patients suspected of having UTUC, irrespective of type of management, will be prospectively collected up to 5 years after inclusion. Data on the patterns of presentation, diagnostics, and treatment as well as short-, mid-, and long-term oncological and functional outcomes will be analyzed. Possible associations between variables, basal characteristics, and outcomes will be tested by multivariable analyses. The methodology will address potential sources of bias and confounders. ResultsThe registry was initiated in November 2014 after obtaining institutional review board approval. Data collection started in December 2014. At the time of submission of this manuscript, 2451 patients from 125 centers from 37 countries were included. Inclusion of patients will be closed 5 years after initiation of the registry. Quality checks will be performed centrally with continuous communication and feedback with the centers to ensure accuracy. The first results are expected in the first trimester of 2020. ConclusionsThis large observational prospective cohort will generate landmark “real-world” data and hypotheses for further studies. We expect these data to optimize the management of UTUC, provide insights on harms and benefits of treatment, and serve as quality control. Trial RegistrationClinicalTrials.gov NCT02281188; https://clinicaltrials.gov/ct2/show/NCT02281188. International Registered Report Identifier (IRRID)DERR1-10.2196/15363

Published
2020
Full Text
View/download PDF

5. From BPH to male LUTS: a 20-year journey of the EAU guidelines

Author

Gravas, Stavros, Malde, Sachin, Cornu, Jean-Nicolas, Gacci, Mauro, Gratzke, Christian, Herrmann, Thomas R. W., Karavitakis, Markos, Mamoulakis, Charalampos, Rieken, Malte, Sakalis, Vasileios I., Schouten, Natasha, Smith, Emma J., Speakman, Mark J., Tikkinen, Kari A. O., Alivizatos, Gerasimos, Bach, Thorsten, Bachmann, Alexander, Descazeaud, Aurelian, Desgrandchamps, François, Drake, Marcus, Emberton, Mark, Kyriazis, Iason, Madersbacher, Stephan, Michel, Martin C., N’Dow, James, Perachino, Massimo, Plass, Karin, Rioja Sanz, Carlos, Umbach, Roland, de Wildt, Michel, Oelke, Matthias, and de la Rosette, Jean J. M. C. H.

Published
2024
Full Text
View/download PDF

7. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus

Author

Tan, Wei Phin, Rastinehad, Ardeshir R, Klotz, Laurence, Carroll, Peter R, Emberton, Mark, Feller, John F, George, Arvin K, Gill, Inderbir S, Gupta, Rajan T, Katz, Aaron E, Lebastchi, Amir H, Marks, Leonard S, Marra, Giancarlo, Pinto, Peter A, Song, Daniel Y, Sidana, Abhinav, Ward, John F, Sanchez-Salas, Rafael, de la Rosette, Jean, Polascik, Thomas J, Authors, Focal Therapy Group, Katz, Aaron, Aminsharifi, Alireza, Lebastchi, Amir, Abreu, Andre, Villers, Arnauld, Schulman, Ariel, Rastinehad, Ardeshir, George, Arvin, Oto, Aytekin, Turkbey, Baris, Malavaud, Bernard, Muller, Berrend, Moore, Caroline, Eberli, Daniel, Margolis, Daniel, Song, Daniel, Lomas, Derek, Orabi, Hazem, Lepor, Herbert, Tan, Hui Meng, Jambor, Ivan, Grummet, Jeremy, Feller, John, Ward, John, Colemen, Jonathan, Gregg, Justin, Tay, Kae Jack, Marks, Leonard, Deane, Leslie, Laguna, M Pilar, Kimura, Masaki, Tsivian, Matvey, Gorin, Michael, Siddiqui, Minhaj, Ukimura, Osamu, Gontero, Paolo, Carroll, Peter, Pinto, Peter, Mozer, Pierre, Arcot, Ro, Taneja, Samir, Ghai, Sangeet, Crouzet, Sebastian, Mehralivand, Sherif, Joniau, Steven, Shoji, Sunao, Shiraishi, Takumi, Polascik, Thomas, Shin, Toshitaka, Lindnet, Uri, Tammisetti, Varaha, van den Bos, Willemien, and Matsuoka, Yoh

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Urologic Diseases, Prostate Cancer, Clinical Research, Ablation Techniques, Aged, Aged, 80 and over, Consensus, Delphi Technique, Humans, Male, Middle Aged, Prostatic Neoplasms, Watchful Waiting, Localized prostate cancer, Focal therapy, Partial gland ablation, Active surveillance, Focal Therapy Group Authors, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundWith the advancement of imaging technology, focal therapy (FT) has been gaining acceptance for the treatment of select patients with localized prostate cancer (CaP). We aim to provide details of a formal physician consensus on the utilization of FT for patients with CaP who are discontinuing active surveillance (AS).MethodsA 3-stage Delphi consensus on CaP and FT was conducted. Consensus was defined as agreement by ≥80% of physicians. An in-person meeting was attended by 17 panelists to formulate the consensus statement.ResultsFifty-six respondents participated in this interdisciplinary consensus study (82% urologist, 16% radiologist, 2% radiation oncology). The participants confirmed that there is a role for FT in men discontinuing AS (48% strongly agree, 39% agree). The benefit of FT over radical therapy for men coming off AS is: less invasive (91%), has a greater likelihood to preserve erectile function (91%), has a greater likelihood to preserve urinary continence (91%), has fewer side effects (86%), and has early recovery post-treatment (80%). Patients will need to undergo mpMRI of the prostate and/or a saturation biopsy to determine if they are potential candidates for FT. Our limitations include respondent's biases and that the participants of this consensus may not represent the larger medical community.ConclusionsFT can be offered to men coming off AS between the age of 60 to 80 with grade group 2 localized cancer. This consensus from a multidisciplinary, multi-institutional, international expert panel provides a contemporary insight utilizing FT for CaP in select patients who are discontinuing AS.

Published
2021

11. Complications and outcomes of tubeless versus nephrostomy tube in percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized clinical trials

Author

Gauhar, Vineet, Traxer, Olivier, García Rojo, Esther, Scarcella, Simone, Pavia, Maria Pia, Chan, Vinson Wai-Shun, Pretore, Eugenio, Wroclawski, Marcelo Langer, Corrales, Mariela, Tiong, Ho Yee, Lim, Ee Jean, Teoh, Jeremy Yuen-Chun, Heng, Chin-Tiong, de la Rosette, Jean, Somani, Bhaskar Kuman, and Castellani, Daniele

Published
2022
Full Text
View/download PDF

13. Newer Advances in Access

Author

de la Rosette, Jean, Kashi, Amir H., Farshid, Saman, Agrawal, Madhu S., editor, Mishra, Dilip K., editor, and Somani, Bhaskar, editor

Published
2022
Full Text
View/download PDF

14. Reassessing Normal Voiding Standards: A Cross-Sectional Study Based on Medical Professionals’ Evaluations with Portable Uroflowmetry and IPSS

Author

Almas, Furkan, primary, Dasdelen, Muhammed Furkan, additional, Seyhan, Zuleyha, additional, Sargolzaeimoghaddam, Maral, additional, Sarg, Arya, additional, Unlu, Omer, additional, Dasdelen, Zehra Betul, additional, Horuz, Rahim, additional, Albayrak, Selami, additional, Kocak, Mehmet, additional, Laguna, Pilar, additional, and de la Rosette, Jean, additional

Published
2024
Full Text
View/download PDF

18. European Association of Urology Section of Urolithiasis and International Alliance of Urolithiasis Joint Consensus on Retrograde Intrarenal Surgery for the Management of Renal Stones

Author

Zeng, Guohua, Zhao, Zhijian, Mazzon, Giorgio, Pearle, Margaret, Choong, Simon, Skolarikos, Andreas, Denstedt, John, Seitz, Christian, Olvera Pasada, Daniel, Fiori, Cristian, Bosio, Andrea, Papatsoris, Athanasios, Méndez Probst, Carlos Enrique, Perez Fentes, Daniel, Ann Git, Kah, Wu, Qinghui, Wiseman, Oliver, Emiliani, Esteban, Farahat, Yasser, Ilker Gökce, Mehmet, Giannakopoulos, Stilianos, Goumas Kartalas, Ioannis, Somani, Bhaskar, Knoll, Thomas, de la Rosette, Jean, Zhong, Jiehui, Vinicius Maroccolo, Marcus, Saltirov, lliya, Chew, Ben, Wang, Kunjie, Lahme, Sven, Giusti, Guido, Ferretti, Stefania, Yong Cho, Sung, Geavlete, Petrisor, Cansino, Ramon, Kamphuis, Guido M., Smith, Daron, Matlaga, Brian R., Ghani, Khurshid D., Bernardo, Norberto, Silva, Andres D., Ng, Anthony C.F., Yang, Sixing, Gao, Xiaofeng, Traxer, Olivier, Miernik, Arkadiusz, Liatsikos, Evangelos, Priyakant Parikh, Kandarp, Duvdevani, Mordechai, Celia, Antonio, Yasui, Takahiro, Aquino, Albert, Alomar, Mohammad, Choonhaklai, Vorapot, Erkurt, Bulent, Glass, Jonathan, Sriprasad, Seshadri, Osther, Palle J., Keeley, Francis X., Jr., Preminger, Glenn M., Cepeda Delgado, Marcos, Beltran Suarez, Edgar, Ye, Zhangqun, and Sarica, Kemal

Published
2022
Full Text
View/download PDF

19. Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results

Author

de la Rosette, Jean, Martov, Alexey, Hurle, Rodolfo, Favre, Gabriel, Mamoulakis, Charalampos, Castanheira de Oliveira, Manuel, Stenzl, Arnulf, Linares-Espinós, Estefania, Trelles Guzmán, Carlos R., Gravas, Stavros, Knoll, Thomas, Boz, Mustafa Yucel, Herrmann, Thomas, and Laguna, Pilar

Published
2022
Full Text
View/download PDF

23. Impact of Pre-Operative Ureteroscopy on Bladder Recurrence Following Nephroureterectomy for UTUC.

Author

Wong, Chris Ho-Ming, Ko, Ivan Ching-Ho, Leung, David Ka-Wai, Liu, Kang, Zhao, Hongda, Alvarez-Maestro, Mario, Pes, Maria del Pilar Laguna, de la Rosette, Jean, and Teoh, Jeremy Yuen-Chun

Subjects
ONCOLOGIC surgery, URINARY organ surgery, URETHRA surgery, URETEROSCOPY, BLADDER tumors, CANCER relapse, RESEARCH funding, NEPHRECTOMY, PREOPERATIVE care, DESCRIPTIVE statistics, MULTIVARIATE analysis, LONGITUDINAL method, KAPLAN-Meier estimator, RESEARCH, PROGRESSION-free survival, CONFIDENCE intervals, PROPORTIONAL hazards models
Abstract

Simple Summary: This research investigates whether a diagnostic technique called ureteroscopy (URS), performed before surgery for removing the kidney and ureter, influences the likelihood of cancer recurrence in the bladder in patients with upper tract urothelial carcinoma (UTUC). Data from a multicentre international registry were analysed to compare patients who underwent URS before their surgery with those who did not. The study found that patients who had URS prior to surgery experienced a higher rate of cancer recurrence in the bladder. These results highlight the need for careful consideration of the use of URS in the diagnostic process for UTUC, as it could affect long-term outcomes. This information is crucial for clinicians in optimizing treatment strategies and improving patient care. (1) Introduction: Diagnostic ureteroscopy (URS) is an important component in the workup of upper tract urothelial carcinoma (UTUC). Whether URS was associated with increased recurrence in the bladder was not fully concluded. The current study aimed to evaluate the implication of URS on the incidences of intravesical recurrence following radical nephroureterectomy (RNU) in non-metastatic UTUC patients without prior history of bladder cancer via multi-institutional data. (2) Patients and Methods: Data were obtained from the Clinical Research Office of the Endourology Society Urothelial Carcinomas of the Upper Tract (CROES-UTUC) registry, a prospective, multicentre database. Patients with non-metastatic UTUC treated with RNU were divided into two groups: those undergoing upfront RNU and those having diagnostic URS prior to RNU. Intravesical recurrence-free survival (IVRS) was the primary endpoint, evaluated through Kaplan–Meier analysis and multivariate Cox regression. Cases with adequate follow-up data were included. (3) Results: The analysis included 269 patients. Of these, 137 (50.9%) received upfront RNU and 132 (49.1%) received pre-RNU URS. The URS group exhibited an inferior 24-month IVRS compared to the upfront RNU group (HR = 1.705, 95% CI = 1.082–2.688; p = 0.020). Multivariate analysis confirmed URS as the only significant predictor of IVR (p = 0.019). Ureteric access sheath usage, flexible ureteroscopy, ureteric biopsy, retrograde contrast studies, and the duration of URS did not significantly affect IVRS. (4) Conclusions: Diagnostic URS prior to RNU was found to be associated with an increased risk of IVR in patients with UTUC. The risk was not significantly influenced by auxiliary procedures during URS. Physicians were advised to meticulously evaluate the necessity of diagnostic URS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Effects of Varicocele Repair on Sperm DNA Fragmentation and Seminal Malondialdehyde Levels in Infertile Men with Clinical Varicocele: A Systematic Review and Meta-Analysis

Author

Cannarella, Rossella, primary, Shah, Rupin, additional, Saleh, Ramadan, additional, Boitrelle, Florence, additional, Hamoda, Taha Abo-Almagd Abdel-Meguid, additional, Singh, Rajender, additional, Salvio, Gianmaria, additional, Toprak, Tuncay, additional, Falcone, Marco, additional, Gul, Murat, additional, Dimitriadis, Fotios, additional, Rambhatla, Amarnath, additional, Russo, Giorgio I., additional, Ko, Edmund, additional, Zini, Armand, additional, Kavoussi, Parviz, additional, Phuoc, Nguyen Ho Vinh, additional, Kandil, Hussein, additional, Ghayda, Ramy Abou, additional, Birowo, Ponco, additional, Gherabi, Nazim, additional, Ceyhan, Erman, additional, Dong, Jie, additional, Malhotra, Vineet, additional, Durairajanayagam, Damayanthi, additional, Kolbasi, Bircan, additional, Bahar, Fahmi, additional, Calik, Gokhan, additional, Çayan, Selahittin, additional, Pinggera, Germar-Michael, additional, Calogero, Aldo E., additional, Rajmil, Osvaldo, additional, Mostafa, Taymour, additional, Atmoko, Widi, additional, Harraz, Ahmed M., additional, Le, Tan V., additional, de la Rosette, Jean, additional, Hakim, Lukman, additional, Pescatori, Edoardo, additional, Sergeyev, Oleg, additional, Rashed, Ayman, additional, Saini, Pallavi, additional, and Agarwal, Ashok, additional

Published
2024
Full Text
View/download PDF

41. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel

Author

Muller, Berrend G, Fütterer, Jurgen J, Gupta, Rajan T, Katz, Aaron, Kirkham, Alexander, Kurhanewicz, John, Moul, Judd W, Pinto, Peter A, Rastinehad, Ardeshir R, Robertson, Cary, de la Rosette, Jean, Sanchez‐Salas, Rafael, Jones, J Stephen, Ukimura, Osamu, Verma, Sadhna, Wijkstra, Hessel, and Marberger, Michael

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Cancer, Biomedical Imaging, Urologic Diseases, Biopsy, Consensus, Humans, Magnetic Resonance Imaging, Male, Patient Selection, Practice Guidelines as Topic, Prostatic Neoplasms, Risk Assessment, Sensitivity and Specificity, Ultrasonography, Interventional, Ultrasound, High-Intensity Focused, Transrectal, United States, prostate cancer, focal therapy, consensus, multiparametric magnetic resonance imaging, prostate biopsies, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectiveTo establish a consensus on the utility of multiparametric magnetic resonance imaging (mpMRI) to identify patients for focal therapy.MethodsUrological surgeons, radiologists, and basic researchers, from Europe and North America participated in a consensus meeting about the use of mpMRI in focal therapy of prostate cancer. The consensus process was face-to-face and specific clinical issues were raised and discussed with agreement sought when possible. All participants are listed among the authors. Topics specifically did not include staging of prostate cancer, but rather identifying the optimal requirements for performing MRI, and the current status of optimally performed mpMRI to (i) determine focality of prostate cancer (e.g. localising small target lesions of ≥0.5 mL), (ii) to monitor and assess the outcome of focal ablation therapies, and (iii) to identify the diagnostic advantages of new MRI methods. In addition, the need for transperineal template saturation biopsies in selecting patients for focal therapy was discussed, if a high quality mpMRI is available. In other words, can mpMRI replace the role of transperineal saturation biopsies in patient selection for focal therapy?ResultsConsensus was reached on most key aspects of the meeting; however, on definition of the optimal requirements for mpMRI, there was one dissenting voice. mpMRI is the optimum approach to achieve the objectives needed for focal therapy, if made on a high quality machine (3T with/without endorectal coil or 1.5T with endorectal coil) and judged by an experienced radiologist. Structured and standardised reporting of prostate MRI is paramount. State of the art mpMRI is capable of localising small tumours for focal therapy. State of the art mpMRI is the technique of choice for follow-up of focal ablation.ConclusionsThe present evidence for MRI in focal therapy is limited. mpMRI is not accurate enough to consistently grade tumour aggressiveness. Template-guided saturation biopsies are no longer necessary when a high quality state of the art mpMRI is available; however, suspicious lesions should always be confirmed by (targeted) biopsy.

Published
2014

42. Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study

Author

Hongda, Zhao, primary, Kang, Liu, additional, Ng, Chi-Fai, additional, de la Rosette, Jean, additional, Laguna, Pilar, additional, Gontero, Paolo, additional, Baard, Joyce, additional, Yildiz, Ozcan, additional, and Teoh, Jeremy Yuen-Chun, additional

Published
2023
Full Text
View/download PDF

44. From BPH to male LUTS: a 20-year journey of the EAU guidelines

Author

Gravas, Stavros, primary, Malde, Sachin, additional, Cornu, Jean-Nicolas, additional, Gacci, Mauro, additional, Gratzke, Christian, additional, Herrmann, Thomas R. W., additional, Karavitakis, Markos, additional, Mamoulakis, Charalampos, additional, Rieken, Malte, additional, Sakalis, Vasileios I., additional, Schouten, Natasha, additional, Smith, Emma J., additional, Speakman, Mark J., additional, Tikkinen, Kari A. O., additional, Alivizatos, Gerasimos, additional, Bach, Thorsten, additional, Bachmann, Alexander, additional, Descazeaud, Aurelian, additional, Desgrandchamps, François, additional, Drake, Marcus, additional, Emberton, Mark, additional, Kyriazis, Iason, additional, Madersbacher, Stephan, additional, Michel, Martin C., additional, N’Dow, James, additional, Perachino, Massimo, additional, Plass, Karin, additional, Rioja Sanz, Carlos, additional, Umbach, Roland, additional, de Wildt, Michel, additional, Oelke, Matthias, additional, and de la Rosette, Jean J. M. C. H., additional

Published
2023
Full Text
View/download PDF

45. Overview of current pharmacotherapeutic options in benign prostatic hyperplasia

Author

Koudonas, Antonios, primary, Anastasiadis, Anastasios, additional, Tsiakaras, Stavros, additional, Langas, Georgios, additional, Savvides, Eliophotos, additional, Mykoniatis, Ioannis, additional, Memmos, Dimitrios, additional, Baniotis, Panagiotis, additional, Vakalopoulos, Ioannis, additional, de la Rosette, Jean, additional, and Dimitriadis, Georgios, additional

Published
2023
Full Text
View/download PDF

46. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer

Author

de la Rosette, Jean, Dominguez-Escrig, Jose, Zhang, Kai, Teoh, Jeremy, Barret, Eric, Ramon-Borja, Juan Casanova, Muir, Gordon, Bohr, Julia, de Reijke, Theo, Ng, Chi-Fai, Leung, Chi-Ho, Sanchez-Salas, Rafael, Laguna, Pilar, Urology, APH - Personalized Medicine, APH - Quality of Care, and CCA - Imaging and biomarkers

Subjects
electroporation, quality of life, Urology, drug-related side effects and adverse reactions, prostatic neoplasms
Abstract

PURPOSE: Our goal was to evaluate the effect of focal vs extended irreversible electroporation on side effects, patient-reported quality of life, and early oncologic control for localized low-intermediate risk prostate cancer patients. MATERIALS AND METHODS: Men with localized low-intermediate risk prostate cancer were randomized to receive focal or extended irreversible electroporation ablation. Quality of life was measured by International Index of Erectile Function, Expanded Prostate Cancer Index Composite questionnaire, and International Prostate Symptom Score. RESULTS: A total of 51 and 55 patients underwent focal and extended irreversible electroporation, respectively. The median follow-up time was 30 months. Rates of erectile dysfunction and rates of adverse events were similar between the 2 groups at 3 months. The focal ablation group seemed to have better International Index of Erectile Function scores at 3 months; it also had a better Expanded Prostate Cancer Index Composite-sexual function score than the extended ablation group across time that was close to statistical significance (mean difference 1.4; 95% CI -0.13 to 2.9, P = .073). There were no significant differences between the 2 groups in other quality-of-life measures. Upon prostate biopsy at 6 months, the rate of residual clinically significant prostate cancer (Gleason ≥3 + 4) was 18.8% and 13.2% in the focal and extended irreversible electroporation groups, respectively, without significant differences. CONCLUSIONS: Focal and extended irreversible electroporation ablation had similar safety profile, urinary function, and oncologic outcomes in men with localized low-intermediate risk prostate cancer. In addition, focal ablation demonstrated superior erectile function outcome over extended irreversible electroporation in the first 3-6 months.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results